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Letters to the EditorBy restricting the analysis to informa-
tion provided only in the text (and
not, eg, extracted from Kaplan–Meier
curves) and considering only the effect
of the longest time of follow-up from
each study, we calculated an OR of
0.82 (95% CI, 0.67–1.02; P ¼ .07).
This shows that in PS analyses the
superiority of the off-pump approach
applies not only to short-term mortality
but also to long-term mortality, albeit
to a smaller degree.
Eventually, the results of current
randomized studies on risk groups
that mirror today’s typical patient pop-
ulations will elucidate the truth about
the differences between the on- and
off-pump approaches.
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Bad Oeynhausen, GermanyTABLE 1. Breakdown of extrapolated cost benefits of cryoprobe
Diagnostic yield with forceps biopsy at Glenfield Hospital, Leicester (%) 77%
Repeat bronchoscopy rate (%) 23%
No. of bronchoscopies with macroscopic tumor/year 132
No. of repeat bronchoscopies needed/year (132 3 23%) 30
Cost of standard bronchoscopy (2010 tariff) £504
Published improved relative increase in yield with cryobiopsy (%) 36%
Estimated diagnostic yield with cryobiopsy at Glenfield Hospital, Leicester (36%
relative increase on 77%) (%)
100%
Cost saving of cryobiopsy to Primary Care Trust (£504 3 30) £15,120
Cost of cryobiopsy equipment (cryosurgery unit and cable, adapter, probes, gas tube,
footswitch)
£7,500
No. of bronchoscopies to prevent to cover costs (7500/504) 15
Total annual costs (service contractþconsumables) £955
Residual cost savings after capital costs (15,120 – 7500) £7,620
Residual cost savings after annual costs (7620 – 955) £6,665
Residual cost savings, year 2 onward (15,120 – 955) £14,165References
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BENEFITS OF CRYOBIOPSY
To the Editor:
I commend the study by Schumann
and colleagues1 that demonstrated the
clear superiority of cryobiopsy over
standard forceps biopsy for endolumi-
nal tumor, showing a 36% relative in-
crease and 24% absolute increase in
yield as the result of larger and less
fragmented samples.1 Unfortunately,
the acquisition of new equipment and
technology is hampered by resource
rationing in health care systems. Be-
cause tariff-base health care systems
require demonstration of cost benefit,
this article provides useful evidence
with which to develop cryobiopsy in
bronchoscopy units. At Glenfield
Hospital, Leicester, which includes
an annual number of 531 fiberoptic
bronchoscopies annually, we have
audited our own diagnostic yield with
forceps biopsy for endoluminal tumor
and found this to be only 77% overall
for 132 cases over 1 year with evi-
dence of tumor (with some variation
between trainees and consultants).2
By assuming a similar number of
bronchoscopies per year with endolu-
minal tumor with a similar yield with
forceps biopsy, this equates to 30 non-
diagnostic bronchoscopies (Table 1).
Under the National Tariffs for 2010
and 2011,3 the total extra annual cost
is calculated to be more than £15,000of Thoracic and Cardiovascular Surgeper year to the Primary Care Trust 9
(Table 1). By assuming a relative in-
crease in performance with cryobiopsy
similar to that reported by Schumann
and colleagues,1 this would translate
to a cost savings of more than
£15,000 per year (Table 1). The capital
cost of the cryobiopsy equipment
(£7500, ERBE Medical UK, personal
communication, May 2010) could be
covered by saving 15 repeat bronchos-
copies, which would take an estimated
6 months (at 30 saved per year; Table
1). After 1 year, residual cost savings
would total more than £6500 despite
deductions for capital, maintenance,
and consumable costs (Table 1). For
subsequent years, residual funds would
be in excess of £14,000 (Table 1).
The data provided by Schumann and
colleagues1 give respiratory physi-
cians the opportunity to provide a ro-
bust financial case for adding
cryobiopsy to their bronchoscopy unit
on the basis it will fund itself in 6
months, according to our own calcula-
tions and experiences. In addition, bet-
ter quality biopsies will provide better
material for bronchoscopic tissue re-
search studies and molecular markers.4
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doi:10.1016/j.jtcvs.2010.04.022Reply to the Editor:
We thank Dr Medford1 for the
valuable additional analysis concern-
ing the cost benefits of cryobiopsy
based on our recently published article
in the Journal.2
We assume that routine use of a flex-
ible cryoprobe to obtain tissue samples
is cost-effective. However, it has to be
considered that cryobiopsies generally
require protected airways (ie, intuba-
tion). In addition, deep sedation using
midazolam or disoprivan, if not general
anesthesia, is required. In most coun-
tries, this makes additional personnel
or an additional physician (eventually
an anesthetist) necessary, which in
turn leads to an increase in costs. Fur-
ther, different health care systems
may have different tariffs for broncho-
scopic procedures, and this might cause
a variation in final cost-effectiveness
between different countries. Studies in-
vestigating the cost-effectiveness are
under way. Most likely, cryobiopsy is
a method that will result in cost savings
over time. In this sense, we absolutely
agree with Dr Medford.
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ARCH REPLACEMENT
COMBINEDWITH STENTED
ELEPHANT TRUNK
IMPLANTATIONDURINGARCH
RECONSTRUCTION
To the Editor:
We read with great interest the re-
cent article by Xydas and colleagues.1
In this study, they introduced a
novel technique using left carotid–
subclavian bypass (CSB) before arch
replacement with staged thoracic stent
grafting to achieve hybrid arch recon-
struction. Compared with the conven-
tional method, the major advantage of
this technique is using prepared CSB
to anastomose the left carotid artery
to the graft before cardiopulmonary
bypass (CPB). Only 2 anastomoses
(anastomoses of the distal graft to the
aorta and the graft to the innominate
artery) must be done during hypo-
thermic circulatory arrest (HCA),
decreasing selective antegrade cere-
bral perfusion (SACP), CPB and aor-
tic crossclamp times, and limiting
HCA.
Currently, HCA with SACP is
widely used as routine means to pro-
tect the central nervous system duringardiovascular Surgery c August 2010aortic arch replacement; however, to
some degree, the safe time of HCA
with SACP is limited. Therefore, the
best way to protect the brain and spinal
cord is to shorten the period of HCA as
much as possible. Even though the
technique of Xydas and associates1
mentioned in this article could reduce
the HCA time by using CSB to com-
plete the anastomosis of the left carotid
artery to the graft off CPB, we still
think a few questions and limitations
need to be considered when using
this method. First, the premise of using
CSB depends on the pathologic
changes of the arch without spreading
to the left subclavian artery. Second,
might the shunt of CSB lead to cere-
bral malperfusion during this short
term? Third, compared with the tech-
nique we used (total arch replacement
combined with stented elephant trunk
implantation, which we called the
‘‘Sun’s procedure’’ 2-4 Xydas’ method
still requires staged thoracic stent
grafting to achieve hybrid arch recon-
struction.
In our opinion, the Sun’s procedure
for arch reconstruction is more effi-
cient, simple, and safe. The Sun
procedure has been advocated and de-
veloped by our research group since
2003.5,6 Herein, we have summarized
the Sun’s surgical procedure and
made a comparison with the CBS pro-
cedure.
A stent graft (MicroPort Medical
Company Limited, Shanghai, China)
(Figure 1) and 4-branched prosthetic
graft (Meadox Hemashield Platinum
4 Branch Graft; Boston Scientific Inc,
Boston, Mass) were used in total arch
replacement combined with stented
elephant trunk implantation. Cannula-
tion of the right axillary artery was
used for CPB and SCP. The arterial
line was bifurcated for the right axil-
lary artery and for lower body perfu-
sion via 1 branch of a 4-branched
prosthetic graft. During cooling, the
proximal ascending aorta was opened
longitudinally, and aortic root proce-
dures could be done if necessary.
HCA was established when the target
